My ePortfolio Register   

pSTAT3 in luminal breast cancer - results from BIG-2-98 trial

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.05.17
Views: 669

Dr Amir Sonnenblick - Hebrew University Medical Center, Jerusalem, Israel

Dr Sonnenblick speaks with ecancer at IMPAKT 2017 about the role of transcription factors in the JAK-STAT pathway, and the role of pSTAT-3 in breast cancer.

He outlines the clinical background of STAT-3, with mixed reporting on tumour suppression and oncogenesis, and describes its validation with improved luminal breast cancer outcomes through pooled analysis and proteomic evaluation.

Dr Sonnenblick sums up the role of pSTAT-3 as associated with an improved outcome, and urges consideration of this any further STAT inhibitory treatments.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence